All In Biotech

Drug Trial Radar · NCT07658183

A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer

A Randomized, Open-Label, Multicenter Phase II Clinical Trial: Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer Patients

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Oct 31, 2027

Study completion May 31, 2028

Sponsor

Sponsor type
Industry
First posted
Jun 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the objective response rates (ORR) of different doses of BL0175 in patients with postmenopausal hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The main questions it aims to answer are: 1. Which dose level of BL0175 demonstrates the optimal ORR? 2. What is the recommended phase 3 dose (RP3D) based on efficacy and safety data across the tested dose levels?

Conditions

  • Breast Cancer (Locally Advanced or Metastatic)

Interventions

  • BL0175 InjectionDrug

    Participants will receive BL0175 Injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), and thereafter on Day 1 of each subsequent 28-day treatment cycle (CnD1, n ≥ 2). Each treatment cycle is defined as 28 consecutive days. Each dose is 250 mg, administered as a unilateral gluteal intramuscular injection. Treatment will continue until disease progression, intolerable toxicity, withdrawal from the study, or study termination/end of study, whichever occurs first.

  • BL0175 InjectionDrug

    Participants will receive BL0175 Injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), and thereafter once on Day 1 of each subsequent 28-day treatment cycle (CnD1). Each treatment cycle is defined as 28 consecutive days. The total dose per administration is 500 mg, administered as bilateral gluteal intramuscular injections at 250 mg per buttock. Treatment will continue until disease progression, intolerable toxicity, withdrawal from the study, or study termination/end of study, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate Evaluated by Blinded Independent Central ReviewTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.